Rabbit Polyclonal MCL1(BH3DomainSpecific) Antibody

+ +

•  

   
     All lanes : Anti-MCL1 Antibody (BH3 Domain Specific) at 1:2000 dilution Lane 1: Raji whole cell lysate Lane 2: Ramos whole cell lysate Lane 3: A431 whole cell lysate Lane 4: F9 whole cell lysate Lane 5: rat heart lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 37 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Western blot analysis of anti-Mcl-1 BH3 Domain Pab (Cat. #P34313) in Ramos cell line lysates (35ug/lane). Mcl-1-BH3(arrow) was detected using the purified Pab.    

•  

   
     Overlay histogram showing A431 cells stained with P34313 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34313,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     Formalin-fixed and paraffin-embedded human breast carcinoma with MCL1 Antibody (BH3 Domain Specific), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.    

The MCL1 (BH3 Domain-Specific) antibody targets the BH3 domain of the myeloid cell leukemia 1 (MCL1) protein, a critical anti-apoptotic member of the BCL-2 family. MCL1 promotes cell survival by binding pro-apoptotic proteins (e.g., BAX, BAK, or BH3-only proteins) via its BH3-binding groove, thereby inhibiting mitochondrial outer membrane permeabilization and apoptosis. Overexpression of MCL1 is linked to cancer progression, therapy resistance, and poor prognosis, making it a therapeutic target. Antibodies specific to the BH3 domain block these interactions, restoring apoptosis in cancer cells.

These antibodies are used in research to study MCL1's role in apoptosis regulation, protein-protein interactions, and mechanisms of drug resistance. They also aid in validating MCL1-targeted therapies, such as BH3 mimetics (e.g., S63845. AMG-176) or proteolysis-targeting chimeras (PROTACs). Clinically, BH3-domain-specific antibodies help identify MCL1-dependent cancers through techniques like immunohistochemistry or immunoblotting. Challenges include ensuring specificity to avoid cross-reactivity with other BCL-2 family members and minimizing toxicity due to MCL1's essential roles in normal tissues (e.g., hematopoietic cells). This antibody class represents a key tool for both mechanistic studies and therapeutic development in oncology.